Cost-Effectiveness of Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Bacteremia and Pneumonia | Zendy

Matthew S. Simon | Zendy; Maroun M. Sfeir | Zendy; David P. Calfee | Zendy; Michael J. Satlin | Zendy

Open Access

Cost-Effectiveness of Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Bacteremia and Pneumonia

Author(s) -

Matthew S. Simon,

Maroun M. Sfeir,

David P. Calfee,

Michael J. Satlin

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00897-19

Subject(s) - ceftazidime/avibactam , bacteremia , carbapenem resistant enterobacteriaceae , pneumonia , enterobacteriaceae , ceftazidime , medicine , avibactam , colistin , carbapenem , enterobacteriaceae infections , intensive care medicine , microbiology and biotechnology , antibiotics , biology , pseudomonas aeruginosa , bacteria , escherichia coli , biochemistry , genetics , gene

Ceftazidime-avibactam (CAZ-AVI) may improve outcomes among patients with carbapenem-resistantEnterobacteriaceae (CRE) infections compared to those with conventional therapies. However, CAZ-AVI’s cost-effectiveness is unknown. We used a decision analytic model to estimate the health and economic consequences of CAZ-AVI-based therapy compared to colistin-based therapy (COL) for a hypothetical cohort of patients with CRE pneumonia or bacteremia over a 5-year horizon.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research